Navigation Links
Release of Cytopia Abstract for CYT997 Oral Presentation at American Society of Clinical Oncology
Date:5/15/2008

MELBOURNE, Australia, May 15 /PRNewswire-FirstCall/ -- Cytopia Limited (ASX: CYT) today announced that the abstract for its upcoming oral presentation on CYT997 at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO) will be accessible to the public via ASCO's website (http://www.asco.org) from 9pm on Thursday 15 May (US EDT).

The oral presentation, entitled "Phase I evaluation of CYT997, a novel cytotoxic and vascular disrupting agent, in patients with advanced cancer" will be presented to the meeting by Dr Jason Lickliter, Clinical Study Chairman on 2 June 2008.

The meeting, to be held in Chicago, attracts more than 30,000 delegates from around the world.

About CYT997

CYT997 is a vascular disrupting agent (VDA) with a dual mechanism of action that shuts down established blood vessels supplying the tumor with nutrients and oxygen as well as being a general cytotoxic agent. The compound, which was discovered by Cytopia in 2003, can be delivered orally as well as intravenously and was the subject of a successful IND application to the US Food and Drug Administration in 2005. Phase I and Phase II clinical studies with CYT997 in different oncology settings are currently underway.

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and development via subsidiaries based in Melbourne, Australia and New York and specializes in discovering new molecules with an improved therapeutic profile for the treatment of cancer.

Website: http://www.cytopia.com.au


'/>"/>
SOURCE Cytopia Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
2. Tourtellotte Solutions Blazes Trail with New Release of Clinical Trial Supply Chain Simulator
3. CEL-SCI Corporation Releases Letter to Shareholders
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. AcroMetrix Releases New OptiQuant(R) HIV-1 Quantification Panel
6. ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients
7. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
8. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
9. Immunosyn Corporation Releases SF-1019 Study Results
10. UCB Announces Positive Phase III Trial Results for Keppra XR(TM) (levetiracetam) Extended-Release Tablets
11. Keppra XR(TM) Extended-Release Tablets Filed with the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 19, 2017  Novartis today announced the publication ... Lung, and Blood Institute (NHLBI) of the National ... patients with treatment-naïve severe aplastic anemia (SAA) achieved ... eltrombopag at the initiation of and concurrently with ... three sequential treatment groups, or cohorts. Cohort 3 ...
(Date:4/18/2017)... , April 18, 2017 Viverae ® , ... announce the integration of IBM ® Watson Campaign ... deliver targeted communications for a personalized experience. Through digital ... on their health in real time. The enhanced experience ... most to members, wherever they are in their journey ...
(Date:4/18/2017)... , April 18, 2017  Socionext Inc. and ... started in 2016, in which Socionext extracts and ... The companies achieved initial results in reading ultrasound ... Artificial Brain SOINN. The results will be introduced ... April 19-21, at booths 4505 & 4507. ...
Breaking Medicine Technology:
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... support, and collaboration, announces Mirroring360 Pro . This new addition to the ... collaboration experience for education and business. , Mirroring360 Pro enables educators, business professionals ...
(Date:4/25/2017)... ... April 25, 2017 , ... A stressful work environment can hurt ... decrease overall productivity and performance in the workplace. The goal of Clearview Resolution Services ... few weeks of April, Clearview Resolution Services will be shutting down the office early ...
(Date:4/25/2017)... ... 25, 2017 , ... The doctors at Wall Centre Dental are now expanding ... and require sedation to receive dental care. The doctors offer three treatment options to ... cleanings to oral surgery, at their dental office in Vancouver. Wall Centre Dental is ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... they rely on contracted partners to help with process innovation in drug formulation ... drug formulation experience along with state-of-the-art analytical equipment in support of their development ...
(Date:4/25/2017)... ... 2017 , ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace ... help but be heartened by the industry’s current surge. But another thing that unifies ... smell.” At last they can simply, safely and effectively end their aroma anguish ...
Breaking Medicine News(10 mins):